Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental drug TPN-101 studied for rare genetic brain disorder

NCT ID NCT05613868

First seen Apr 25, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This early study tested an experimental drug called TPN-101 in people with Aicardi-Goutières syndrome (AGS), a rare genetic disorder that causes severe brain inflammation. The goal was to see if the drug could reduce abnormal immune system activity and check for side effects. Only 4 people took part before the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AICARDI-GOUTIÈRES SYNDROME (AGS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Istituto Neurologico Casimiro Mondino

    Pavia, 27100, Italy

  • Laboratory of Neurogenetics and Neuroinflammation Imagine Institute - INSERM U1163

    Paris, 75015, France

  • Presidio Ospedale dei Bambini [Children's Hospital]

    Brescia, 25123, Italy

  • Royal Hospital for Children and Young People

    Edinburgh, EH9 1LF, United Kingdom

  • SST Fatebenefratelli Sacco

    Milan, 20154, Italy

Conditions

Explore the condition pages connected to this study.